VERACYTE, INC. (VCYT)
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
📈 **POSITIVE** • Medium confidence analysis (75%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business